PharmAla Biotech Holdings, Inc.
0.17
CAD
-0.01
(-8.33%)
ISIN
CA71719L1067
CUSIP
71719L106
Return %
Stock
S&P 500
1Y
50.00
14.20
3Y
26.92
81.12
5Y
- -
68.34
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Quarterly Revenue
CAD
•
in mil. unless spec.Quarterly Earnings Per Share
CAD
•
in mil. unless spec.Quarterly Dividends Per Share
CAD
•
in mil. unless spec.Company Description
- CEO
- Nicholas Kadysh
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1055 West Georgia Street Toronto BC Canada V6E 4N7
- IPO Date
- Jan 11, 2022
- Website
- pharmala.ca
- Similar Companies
- Business
- Pharmala Biotech Holdings Inc. (MDMA.CN) is a Canadian biotechnology company focused on the research, development, manufacturing, and sale of clinical-grade MDMA and MDXX-class active pharmaceutical ingredients (APIs) and drug products for clinical research, therapeutic use in select jurisdictions, and emerging commercial applications; its core offerings include GMP-manufactured LaNeo™ MDMA in raw API, encapsulated tablets (such as 40mg capsules), and formulations, alongside novel MDXX compounds like PharmAla-1 (P-1), ALA-002 (a non-racemic MDMA enantiomer mixture), APA-001, and APA-02, with ongoing preclinical research into improved safety profiles and novel delivery mechanisms. The company serves academic and commercial researchers, clinicians via programs like Health Canada's Special Access Program and Australia's TGA Authorised Prescriber Scheme, and partners in clinical trials globally, generating revenue from product sales, royalties on intellectual property licensing, and joint venture activities. Founded in 2020 and headquartered in Toronto, Ontario, Pharmala Biotech Holdings operates primarily in Canada with international reach through exports and its 50% ownership in Cortexa Pty Ltd., an Australian joint venture with Vitura Health Limited established in May 2023 for MDMA and psilocybin manufacturing and distribution. Recent developments include the completion of a continuance to Ontario in December 2024, enhancing its corporate structure; closure of a private placement in April 2024 raising $750,000 and an updated base shelf prospectus for up to C$30 million in potential financing; granting of U.S. patents in fiscal 2024 for APA-001 (patent 12042478 in July 2024), ALA-002 (patent 12,053,452 in August 2024), and composition-of-matter allowances for P-1 and ALA-002; fiscal 2024 revenue growth to over $1.0 million (95% year-over-year increase, driven by 73% higher MDMA sales); launch of a Prescribers Portal in May 2024 for direct clinician access; first shipments of MDMA and psilocybin to Cortexa in November 2023 and batch manufacturing commencement there in April 2024; qualification for OTCQB trading under PMBHF (later MDXXF) in September 2023; strategic agreements with Clariti Strategic Advisors (November 2023) and Intellectual Property Ontario (February 2024, securing $35,000 non-dilutive grant); appointment of William Avery as CFO effective October 2024; and terminations of agreements with Red Light Holland (September 2024) and CCrest Labs (October 2024) to streamline operations.
Company News
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech